FDA Aligns with Vera Therapeutics on Accelerated Atacicept Approval Pathway
VERA sits 83% above its 52-week low of $18.79.
Summary
Vera Therapeutics announced FDA alignment on an accelerated timeline for atacicept's eGFR results and sBLA submission, moving up potential full approval for its IgA Nephropathy treatment.
Key Events · Product Development and Regulatory · VERA
-
FDA Alignment for Atacicept
Vera Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in adults with IgA Nephropathy.
-
Accelerated Timeline for Results
The eGFR results are now expected in the third quarter of 2026, an earlier timeline than previously anticipated.
-
Path to Full Approval
Pending these results, the company plans to submit a supplemental Biologics License Application (sBLA) for full approval of atacicept in the fourth quarter of 2026.
Analysis · VERA · Life Sciences
Vera Therapeutics has secured alignment with the FDA on an earlier analysis plan for atacicept's ORIGIN 3 eGFR results, which are now expected in Q3 2026. This accelerates the potential submission of a supplemental Biologics License Application for full approval in Q4 2026, providing a clearer and faster path to market for its key IgA Nephropathy drug. This positive regulatory update for a lead candidate is a significant development for the company.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VERA was trading at $34.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.79 to $56.05. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.